Clinical and Epidemiological Profile of Dolutegravir Use and Antiretroviral Resistance in Honduras

Comprehensive care services (SAIs) play a pivotal role in implementing preventive strategies by offering treatments that have demonstrated efficacy, as exemplified by dolutegravir (DTG). This medication has been employed in various clinical settings because of its pronounced genetic barrier and high tolerance. To characterize the clinical and epidemiological use of dolutegravir in people living with HIV (PLHIV) treated for SAI in Honduras. Cross-sectional studies and secondary analyses of the 2020 to 2021 phenotypic database were performed with SPSS (version 20.0). Ethics Committee approval (057-2021). Out of 2,984 records with sociodemographic data, 44% were women, and 56% were men. The population included 2,221 general population patients, 684 men who have sex with men (MSM), 185 Garifuna, 36 trans women, 8 bisexuals, 6 pregnant women, and 2 prisoners. The average age was 39.5 years. First-line ARVs are the most commonly used type of SAI. The National Cardiopulmonary Institute was the center with the highest use of dolutegravir, with 37.7% of patients receiving it. Among the 3,533 antiretroviral therapy (ART) patient records, 80.1% achieved complete viral suppression (viral load <1,000 copies), with a 95% confidence interval of 78.7%-81.3%. High viral loads were observed in PLHIV receiving ART, regardless of the population type. Monitoring of antiretroviral resistance through phenotypic and genotypic testing is crucial for optimizing HIV treatment in Honduras.